Compare moats
Up to three covered companies, band by band. Every call is a curated editorial judgment, never a disclosed figure — and every band carries its cited basis.
| Eli Lilly and Company | Ciena | Micron | |
|---|---|---|---|
| Moat rating | wide Eli Lilly's FY2025 10-K states "Intellectual property protection is critical" and that compound patents provide roughly 20-year market exclusivity ("patents in each relevant country last for a period of 20 years"), warning that loss of patent protection causes a "severe and rapid decline in revenues." Backed by an 83.0% gross margin (up from 81.3% in 2024) and a fast-growing, patent-protected incretin franchise (Mounjaro +99%, Zepbound +175% in 2025), the economic moat is wide and durable. Source: LLY FY2025 10-K. | narrow Ciena's FY2025 10-K describes a technology position that has held but does not lock customers in. On the durable side, the strategy is to "build on and expand our global leadership in optical networking", resting on "our proprietary WaveLogic™ coherent modem technology" and approximately 2,400 issued patents with 800 more pending as of December 2, 2025. On the limiting side, the same filing says competition "remains intense" and features "aggressive selling efforts, including using significant pricing pressure to displace incumbent vendors", that "our customer contracts generally do not include minimum or guaranteed purchases", and that "there is no assurance that we will maintain our incumbency". Concentration cuts the same way: the five largest customers contributed approximately 50% of fiscal 2025 revenue, one cloud provider approximately 18%. Its income statement reports gross profit of $1,878.9M on $4,386.5M of revenue in FY2023, $1,719.6M on $4,015.0M in FY2024 and $2,004.9M on $4,769.5M in FY2025. Self-described leadership in its segments, with customers that are re-won deal by deal, is a narrow moat. | narrow Micron sits in a three-firm DRAM oligopoly (with Samsung and SK hynix), holds "over 60,000 patents" and leading-edge process technology (industry-first 1-gamma EUV DRAM node in FY2025), yet its FY2025 10-K concedes competitors "may use aggressive pricing" and "may have a larger market share," and consolidated gross margin swung from negative 9% (FY2023) to 40% (FY2025) — a real but commodity-cyclical, non-durable advantage. |
| Moat type | intangibles ip Per the LLY FY2025 10-K, the pharma protection "anticipated to be of most relevance" is "patents claiming the active ingredient (the compound patent)," supplemented by regulatory data protection, FDA approvals, and brands — i.e., intangible assets. The 10-K notes that without such protection, products face intense generic and biosimilar price competition that erodes revenue quickly. | intangibles ip The FY2025 10-K locates the advantage in owned technology rather than in customer lock-in: "The success of our business and technology leadership depends significantly on our proprietary and internally developed technology." That technology is centred on WaveLogic, which Ciena's fiscal Q3 2026 earnings presentation (the source of the first two product rows below) defines as "Ciena's proprietary family of coherent optical chips — the core technology inside most of our networking products", and it reaches beyond Ciena's own systems: the 10-K's coherent pluggable transceivers use WaveLogic "for use within our systems and third-party equipment". Switching costs are the weaker candidate, because the same filing describes operators disaggregating line systems from modems and competitors using price to displace incumbents. | intangibles ip The 10-K roots Micron's edge in proprietary technology and IP: "over 60,000 patents" granted as of Aug 28, 2025, "significant investments to develop proprietary product and process technology," the industry's first 1-gamma (EUV) DRAM node, ninth-generation G9 NAND, and HBM4 samples to key AI customers. |
| Leadership | co leader Duopoly with Novo Nordisk: Novo's own FY2025 20-F names "Novo Nordisk and Eli Lilly [as] the most significant companies measured by market share" in the global diabetes and GLP-1 markets. Lilly is ascendant — the 20-F concedes Wegovy's years-long US anti-obesity prescription lead "was overtaken by a competing GLP-1 based product in the beginning of 2025" (Lilly's tirzepatide) — but Novo still cites Ozempic as "the leading product by sales," so co-leader is the honest band. Sources: Novo Nordisk FY2025 20-F; LLY FY2025 10-K. | co leader Slide 6 of Ciena's fiscal Q3 2026 earnings presentation of 2026-09-03 (https://s25.q4cdn.com/550667411/files/content_files/Ex-99-2-2026-Q3-Earnings-Presentation_FINAL-1.pdf) lists "#1 in Data Center Interconnect Globally" (Dell'Oro Group), "#1 in Total Optical Networking in N. America" (Cignal AI, Dell'Oro Group, Omdia) and "#1 in Submarine Networks Globally" (Omdia), with market share measured as of Q2 2026 excluding China, and a caveat that Ciena "has not independently verified" the analyst data. On the company's own presentation of that data, that is the front rank in its core segments, but the presentation does not claim the global lead in total optical networking, and the FY2025 10-K says competition is "dominated by a small number of very large, multi-national companies" - Nokia, Huawei, Cisco, Hewlett Packard Enterprise and ZTE - many of which have "substantially greater financial, operational and marketing resources, and broader product offerings". A shared front rank, led by Ciena where the company-reported rankings measure it, rather than an uncontested one. | co leader A member of the three-supplier DRAM oligopoly and at the technology frontier (industry-first 1-gamma EUV node), but the smallest of the three by share — the 10-K acknowledges competitors "may have a larger market share" — and a later entrant scaling up in HBM behind SK hynix and Samsung. |
| Pricing power | moderate Mixed. The LLY 10-K shows an 83.0% gross margin (up 1.7pp), evidence of strong list-price power on exclusive branded drugs; but it repeatedly notes 2025 revenue growth was "partially offset by lower realized prices" for both Mounjaro and Zepbound, alongside heavy PBM/formulary rebate pressure and default anti-obesity coverage restrictions (e.g., US self-insured employers "must generally opt in" for obesity-drug coverage). Net pricing power is therefore moderate, not strong. | moderate Moderate, and improving. The FY2025 10-K's income statement reports gross profit of $1,878.9M on $4,386.5M, $1,719.6M on $4,015.0M and $2,004.9M on $4,769.5M of revenue for FY2023-FY2025, in a market where, the filing says, rivals use "significant pricing pressure to displace incumbent vendors" and "price and total cost of ownership" heads the list of competitive factors. Since then the AI build-out has lifted gross margin: Ciena's fiscal Q3 2026 earnings presentation (https://s25.q4cdn.com/550667411/files/content_files/Ex-99-2-2026-Q3-Earnings-Presentation_FINAL-1.pdf) reports GAAP gross margin of 45.4% against 41.3% a year earlier, on revenue up 37% year over year, and guides fiscal 2027 adjusted gross margin to 45% to 46%. The presentation does not say how much of that is price rather than mix or volume, and the 10-K warns that AI-related demand has led to "a constrained supply environment" that can raise component costs. | weak Memory is a commodity with cyclical ASPs: the 10-K flags "volatility in average selling prices" and competitors' "aggressive pricing" as key risks, and consolidated gross margin swung from -9% (FY2023) to 22% (FY2024) to 40% (FY2025), marking Micron largely as a cyclical price-taker; contract-based, supply-tight HBM is a partial exception. |
| Summary | Lilly's moat rests on patent-protected, FDA-approved branded medicines led by its tirzepatide incretin franchise: per the FY2025 10-K, Mounjaro ($22.97B) and Zepbound ($13.54B) together generated roughly 56% of 2025's $65.2B revenue (up 99% and 175% respectively), while compound patents confer ~20-year market exclusivity and support an 83.0% gross margin. Durable competition only emerges after patents and regulatory data protection lapse, at which point the 10-K warns generics and biosimilars drive a "severe and rapid decline in revenues." | Ciena is the optical-transport specialist among networking vendors - its fiscal Q3 2026 earnings presentation calls it "the only pure-play optical systems provider operating at scale today" - and its FY2025 10-K builds the business on one proprietary technology, the WaveLogic coherent modem, carried into the 6500 Packet-Optical Platform, Waveserver data center interconnect systems, the 6500 RLS photonic line system and coherent pluggable transceivers sold for Ciena's own systems and third-party equipment. Analyst rankings the company cites in that presentation, which it says it "has not independently verified", put Ciena first in data center interconnect globally, in total optical networking in North America and in submarine networks globally (Q2 2026, excluding China). The AI build-out has turned it into more of a cloud supplier than a telecom one: cloud providers were 53% of fiscal Q3 2026 revenue, revenue rose 37% year over year, and GAAP gross margin reached 45.4%. The 10-K is equally clear about why the position is narrow rather than wide. Competition is "dominated by a small number of very large, multi-national companies", many with greater resources; rivals use pricing to displace incumbents; contracts carry no minimum or guaranteed purchases; the five largest customers were about half of fiscal 2025 revenue; and disaggregation lets an operator buy the line system from one vendor and the modem from another, while the push into data-center interconnects brings Ciena up against Marvell, Credo and Broadcom. | Micron is one of only three scaled DRAM suppliers (with Samsung and SK hynix) and a leading-edge NAND maker, defended by proprietary product and process technology and more than 60,000 granted patents. In FY2025 it shipped the industry's first 1-gamma (EUV) DRAM production node and sampled HBM4 36GB 12-high to multiple key customers for next-generation AI platforms, evidencing process-technology leadership in AI memory (FY2025 10-K). |
| Chain position | Upstream branded-drug originator. Per the FY2025 10-K, US distribution flows through three wholesalers (McKesson, Cencora, Cardinal Health), each accounting for over 10% of consolidated revenue, into consolidated PBMs/payers whose formularies and rebate demands constrain net price; Lilly is also expanding a direct-to-patient channel, LillyDirect. | Ciena sits between optical-component suppliers and the operators building AI-era networks. Upstream, its FY2025 10-K says its products include "optical and electronic components for which reliable, high-volume supply is often available only from sole or limited sources", built by contract manufacturers with facilities in Canada, Mexico, Thailand, Vietnam and the United States; at November 1, 2025 it carried $826.2 million of inventory and $2.1 billion of purchase commitments. Downstream, the fiscal Q3 2026 earnings presentation puts direct cloud providers at 53% of the quarter's revenue against 37% for service providers, and describes its products as the links between data centers (data center interconnect) and between distributed AI training clusters ("scale-across"). | US-based supplier of the memory tier of the AI stack — DRAM, HBM and NAND; the 10-K notes cloud servers for AI and data-centric workloads "require significantly increasing quantities of DRAM, including HBM," and Micron sampled HBM4 to power next-generation AI platforms. |
| Products (share / barrier) |
|
|
|
| Long-horizon vote | +0.30 at weight 0.20 · swarm neutral Editorial prior, not backtested. | +0.13 at weight 0.20 · swarm neutral Editorial prior, not backtested. | +0.05 at weight 0.20 · swarm bullish Editorial prior, not backtested. |